Oxaliplatin combined with S-1 capsule in the treatment of 62 cases with advanced gastric cancer

Objective： The aim of this study was to evaluate the efficacy and safety profile of DeFazio （S-l） combined with oxaliplatin against unresectable advanced or metastatic gastric cancer. Methods： Oxaliplatin was given intravenously at 130 mg/m2 for 2 h on dl and S-1 was administered bid. at 80 mg/m2/day on d1-14 followed by a 7-day rest during the 3-week schedule. Results： All 62 patients were assessed for efficacy and adverse events. The response and disease control rates were 47.3% and 80.8%, respectively. The median time to progression was 7.8 months, and the median overall survival was 11.6 months. The grade 3/4 adverse events were hematological toxicities, including neutropenia （11.3%）, thrombocytopenia （9.7%） and gastrointestinal reactions （6.5%）. Conclusion： The SOX regimen （oxaliplatin, 130 mg/m2 d l; S-1, 80 mg/m2/day, bid. d1-14, q3w） provide a favorable efficacy and safety profile in patients with advanced gastric cancer.

奥沙利铂联合替吉奥方案与XELOX方案在晚期结直肠癌治疗中的副作用对比

目的探讨奥沙利铂联合替吉奥方案与XELOX方案在晚期结直肠癌治疗中的副作用。方法 80例晚期结肠癌患者,随机分为试验组和对照组,每组40例。对照组患者采取XELOX方案治疗,试验组患者采用奥沙利铂联合替吉奥方案治疗,比较两组患者的副作用发生情况。结果两组患者骨髓抑制、胃肠道反应、口腔黏膜病变发生率比较差异无统计学意义(P>0.05);试验组手足综合征和肝损伤发生率分别为20.0%、15.0%,均高于对照组的5.0%、2.5%,差异有统计学意义(P<0.05)。结论对直肠癌晚期患者使用XELOX方案其副作用明显低于奥沙利铂联合替吉奥方案,值得在临床推广。